Chandra P Belani

Summary

Affiliation: Pennsylvania State University
Country: USA

Publications

  1. Belani C. The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors. Cancer Invest. 2010;28:413-23 pubmed publisher
    ..Irreversible epidermal growth factor receptor tyrosine kinase inhibitors are an emerging class of agents that may have the potential to overcome and prevent the emergence of such mutation-related resistance. ..
  2. Belani C, Ramalingam S, Perry M, LaRocca R, Rinaldi D, Gable P, et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol. 2008;26:468-73 pubmed publisher
    ..All efficacy parameters were similar between the two treatment arms. The favorable nonhematologic toxicity profile of arm 1 makes this an alternative treatment option for patients with advanced NSCLC. ..
  3. Belani C, Brodowicz T, Ciuleanu T, Krzakowski M, Yang S, Franke F, et al. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol. 2012;13:292-9 pubmed publisher
    ..Eli Lilly. ..